Coagulation Factor Deficiency Market
完整報告名稱與涵蓋範圍
Coagulation Factor Deficiency Market Size, Share & Trends Analysis Report By Deficiency Type (Hemophilia A, Hemophilia B, Von Willebrand Disease, Factor XI Deficiency, Factor XIII Deficiency, and Others), By Product Type, By End Users, By Region, And By Segment Forecasts, 2024-2031
報告摘要
The Coagulation Factor Deficiency Market on a global scale was estimated at USD 5.50 Bn in 2023 and is set to attain USD 9.60 Bn by 2031, with a projected CAGR of 7.36% between 2024 and 2031.
The Coagulation Factor Deficiency sector involves a medical disorder characterized by an inadequate or malfunctioning of coagulation factors, which are proteins responsible for blood clotting. This domain has witnessed considerable transformation owing to technological breakthroughs and shifting healthcare dynamics.
The market's upward path is propelled by expanding healthcare spending, technological evolution, and the expanding focus on personalized and precision-based approaches in healthcare.
Segmental analysis reveals differentiated growth across product categories, applications, and geographical regions, with certain niches demonstrating above-average expansion potential.
Regional dynamics show North America and Europe as established hubs, with the Asia-Pacific region set to deliver the strongest growth trajectory through the forecast period, propelled by demographic shifts and policy support.
Industry participants are deploying a range of strategies—including partnerships, mergers, technological investments, and portfolio diversification—to consolidate their market standing.
Through rigorous analysis of market trends, growth catalysts, restraints, and opportunities, this study offers valuable perspectives for companies, investors, and policymakers navigating this evolving landscape.
授權報價
| Single User PDF | $4,500 USD |
| Global Site License PDF | $9,500 USD |
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Coagulation Factor Deficiency Market Snapshot
Chapter 4. Global Coagulation Factor Deficiency Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis – Porter's Five Forces Analysis
4.7. Competitive Landscape & Market Share Analysis
4.8. Impact of Covid-19 Analysis
Chapter 5. Market Segmentation 1: By Product Type Estimates & Trend Analysis
5.1. By Product Type, & Market Share, 2019 & 2031
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following By Product Type:
5.2.1. Plasma-derived coagulation Factor Concentrates
5.2.2. Recombinant Coagulation Factor Concentrates
5.2.3. Biologics
5.2.4. Desmopressin
5.2.5. Others
Chapter 6. Market Segmentation 2: By Deficiency Type Estimates & Trend Analysis
6.1. By Deficiency Type & Market Share, 2019 & 2031
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following By Deficiency Type:
6.2.1. Hemophilia A
6.2.2. Hemophilia B
6.2.3. Von Willebrand Disease
6.2.4. Factor XI Deficiency
6.2.5. Factor XIII Deficiency
6.2.6. Others
Chapter 7. Market Segmentation 3: By End-User Estimates & Trend Analysis
7.1. By End-User & Market Share, 2019 & 2031
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following By End-User:
7.2.1. Hospitals
7.2.2. Clinics
7.2.3. Homecare
7.2.4. Others
Chapter 8. Coagulation Factor Deficiency Market Segmentation 4: Regional Estimates & Trend Analysis
8.1. North America
8.1.1. North America Coagulation Factor Deficiency Market revenue (US$ Million) estimates and forecasts By Product Type, 2024-2031
8.1.2. North America Coagulation Factor Deficiency Market revenue (US$ Million) estimates and forecasts By Deficiency Type, 2024-2031
8.1.3. North America Coagulation Factor Deficiency Market revenue (US$ Million) estimates and forecasts By End-User, 2024-2031
8.1.4. North America Coagulation Factor Deficiency Market revenue (US$ Million) estimates and forecasts by country, 2024-2031
8.2. Europe
8.2.1. Europe Coagulation Factor Deficiency Market revenue (US$ Million) By Product Type, 2024-2031
8.2.2. Europe Coagulation Factor Deficiency Market revenue (US$ Million) By Deficiency Type, 2024-2031
8.2.3. Europe Coagulation Factor Deficiency Market revenue (US$ Million) By End-User, 2024-2031
8.2.4. Europe Coagulation Factor Deficiency Market revenue (US$ Million) by country, 2024-2031
8.3. Asia Pacific
8.3.1. Asia Pacific Coagulation Factor Deficiency Market revenue (US$ Million) By Product Type, 2024-2031
8.3.2. Asia Pacific Coagulation Factor Deficiency Market revenue (US$ Million) By Deficiency Type, 2024-2031
8.3.3. Asia Pacific Coagulation Factor Deficiency Market revenue (US$ Million) By End-User, 2024-2031
8.3.4. Asia Pacific Coagulation Factor Deficiency Market revenue (US$ Million) by country, 2024-2031
8.4. Latin America
8.4.1. Latin America Coagulation Factor Deficiency Market revenue (US$ Million) By Product Type, (US$ Million) 2024-2031
8.4.2. Latin America Coagulation Factor Deficiency Market revenue (US$ Million) By Deficiency Type, (US$ Million) 2024-2031
8.4.3. Latin America Coagulation Factor Deficiency Market revenue (US$ Million) By End-User, (US$ Million) 2024-2031
8.4.4. Latin America Coagulation Factor Deficiency Market revenue (US$ Million) by country, 2024-2031
8.5. Middle East & Africa
8.5.1. Middle East & Africa Coagulation Factor Deficiency Market revenue (US$ Million) By Product Type, (US$ Million) 2024-2031
8.5.2. Middle East & Africa Coagulation Factor Deficiency Market revenue (US$ Million) By Deficiency Type, (US$ Million) 2024-2031
8.5.3. Middle East & Africa Coagulation Factor Deficiency Market revenue (US$ Million) By End-User, (US$ Million) 2024-2031
8.5.4. Middle East & Africa Coagulation Factor Deficiency Market revenue (US$ Million) by country, 2024-2031
Chapter 9. Competitive Landscape
9.1. Major Mergers and Acquisitions/Strategic Alliances
9.2. Company Profiles
9.2.1. Pfizer Inc
9.2.2. Grifols
9.2.3. Biogen
9.2.4. Octapharma
9.2.5. Baxter
9.2.6. Bayer
9.2.7. CSL Behring
9.2.8. Novo Nordisk
9.2.9. Greencross
9.2.10. Kedrion
9.2.11. BPL
9.2.12. Hualan Bio
9.2.13. RAAS
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們